| 000 | 01716cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030332.0 | ||
| 008 | 110108s2010 ua f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.11.01.M.Sc.2010.Ay.P | ||
| 100 | 0 | _aAyat Abdelfattah Hassan Mohammad | |
| 245 | 1 | 0 |
_aPharmacotherapy for refractory cancer pain / _cAyat Abdelfattah Hassan Mohammad ; Supervised Magdi Ramzi Iskander , Salwa Hefnawy , Gomaa Zohry Hussien |
| 246 | 1 | 5 | _aالعلاج الدوائى لألام السرطان المستعصيه |
| 260 |
_aCairo : _bAyat Abdelfattah Hassan Mohammad , _c2010 |
||
| 300 |
_a130 P. ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Anaesthesia | ||
| 520 | _aThe most effective and most appropriate treatment for moderate to severe cancer-induced pain, and they remain the best front-line treatment for cancer pain patients. However, care must be taken to closely monitor patients for potential adverse effects of opioids. Pain is the first symptom of cancer in 20-50% of all cancer patients, and 75-90% of advanced or terminal cancer patients suffer from chronic pain syndrome related to chemotherapy, failed treatment, and/or tumor progression¹ ² | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aPain | |
| 653 | 4 | _aPharmacotherapy | |
| 653 | 4 | _aRefractory | |
| 700 | 0 |
_aGomaa Zohry Hussien , _eSupervisor |
|
| 700 | 0 |
_aMagdi Ramzi Iskander , _eSupervisor |
|
| 700 | 0 |
_aSalwa Hefnawy , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c32548 _d32548 |
||